The Surge in Placenta Accreta: What Anesthesia Providers Need to Know

Placenta accreta is one of the most dangerous and rapidly growing challenges in obstetrics, and CRNAs are often on the front lines when things go wrong. This week we’re joined by OB anesthesia specialists Kira Bruck, CRNA and Kelsey Getzloff, DNP, CRNA to share the latest research, discuss the reasons behind the increase in cases, and outline essential anesthesia strategies for managing high-risk deliveries. Coordination, communication, and preparation saves lives and this episode will help inform CRNAs about what’s most important to know about accreta cases. Here’s some of what we discuss in this episode: 🧠 Understanding the placenta accreta spectrum: accreta, increta, percreta ⚠️ Why diagnosis is missed in 50% of cases and what that means for CRNAs 💉 Anesthesia strategies for known vs. unknown accreta cases 💬 Real-world insights from a high-volume OB anesthesia team 🔄 How CRNAs can advocate for transfers to higher levels of care   Catch Sharon Live at the 53rd Annual Refresher Course for Nurse Anesthetists! Join Sharon this November 14–16, 2025, at the Hilton Hotel in Walt Disney World Village, Florida, for the Frank Moya Continuing Education Program’s annual conference. She’ll be delivering four insightful talks as part of the guest faculty lineup. Don’t miss this chance to learn, connect, and recharge—with some Disney magic on the side!  Click here for more details and to register   Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here (and directly submit to the NBCRNA): https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate  Support Team Emma Kate: https://grouprev.com/haloswalk2024-shannon-shannon-brekken

There are no comments yet.

Please log in to write the first comment.